Challenges and strategies: the immune responses in gene therapy
- PMID: 15250039
- DOI: 10.1002/med.20009
Challenges and strategies: the immune responses in gene therapy
Abstract
The host immune responses, including T lymphocytes mediated immune response and humoral immune responses are the important parts of the challenges in gene therapy. There are some potential immunostimulants in gene delivery systems, such as viral and non-viral vectors. Viral gene products, transgene products, viral proteins derived from viral particles required by dead-end infection, and CpG DNA in plasmid may play important roles in inducing the host immune responses when foreign genes are transferred into the targeted tissues. The immune responses should lead to many problems in gene therapy: transient expression of therapeutic gene, non-efficient re-administration of the same vectors, and severe side-effects in clinical trials. Although RNAi may act as gene therapeutic agent for suppression of specific gene expression, little attention has been given to the potential non-specific effects that might be induced. It was reported that small interfering RNAs (siRNAs) can induce the host interferon response following transfected to mammalian cells. Facing these challenges, a number of studies have been focused on taking measures to solve them, such as immunosuppression, selection of different administration routes and dose of the vectors, using the tissue-specific promoters and modifying the vectors.
Copyright 2004 Wiley Periodicals, Inc.
Similar articles
-
How not to be seen: immune-evasion strategies in gene therapy.Gene Ther. 2008 Feb;15(4):239-46. doi: 10.1038/sj.gt.3303082. Epub 2007 Nov 29. Gene Ther. 2008. PMID: 18046427 Review.
-
Innate immune response induced by gene delivery vectors.Int J Pharm. 2008 Apr 16;354(1-2):9-15. doi: 10.1016/j.ijpharm.2007.06.012. Epub 2007 Jun 16. Int J Pharm. 2008. PMID: 17640834 Review.
-
Antivector and antitransgene host responses in gene therapy.Curr Opin Mol Ther. 2000 Aug;2(4):376-82. Curr Opin Mol Ther. 2000. PMID: 11249767 Review.
-
Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy.Gene Ther. 2003 Jun;10(11):955-63. doi: 10.1038/sj.gt.3302037. Gene Ther. 2003. PMID: 12756416 Review.
-
Towards safe, non-viral therapeutic gene expression in humans.Nat Rev Genet. 2005 Apr;6(4):299-310. doi: 10.1038/nrg1577. Nat Rev Genet. 2005. PMID: 15761468 Review.
Cited by
-
RNA interference: from gene silencing to gene-specific therapeutics.Pharmacol Ther. 2005 Aug;107(2):222-39. doi: 10.1016/j.pharmthera.2005.03.004. Pharmacol Ther. 2005. PMID: 15908010 Free PMC article. Review.
-
Suppression of lung cancer progression by biocompatible glycerol triacrylate-spermine-mediated delivery of shAkt1.Int J Nanomedicine. 2012;7:2293-306. doi: 10.2147/IJN.S29152. Epub 2012 May 4. Int J Nanomedicine. 2012. PMID: 22619562 Free PMC article.
-
Pancreatic Transdifferentiation Using β-Cell Transcription Factors for Type 1 Diabetes Treatment.Cells. 2022 Jul 8;11(14):2145. doi: 10.3390/cells11142145. Cells. 2022. PMID: 35883588 Free PMC article. Review.
-
Transcriptional Targeting and MicroRNA Regulation of Lentiviral Vectors.Mol Ther Methods Clin Dev. 2019 Jan 8;12:223-232. doi: 10.1016/j.omtm.2018.12.013. eCollection 2019 Mar 15. Mol Ther Methods Clin Dev. 2019. PMID: 30775404 Free PMC article. Review.
-
Plasmid CpG depletion improves degree and duration of tumor gene expression after intravenous administration of polyplexes.Pharm Res. 2008 Jul;25(7):1654-62. doi: 10.1007/s11095-008-9558-7. Epub 2008 Mar 4. Pharm Res. 2008. PMID: 18317886 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
